Anti-CDK6 Antibody

CDK6 drives G1 to S phase progression by partnering with cyclin D to phosphorylate the retinoblastoma protein, making it a frequent focus in cancer biology and cell cycle research. This polyclonal reagent from Antibodies.com is raised in rabbit and supplied unconjugated in a 100 µl volume, suitable for direct integration into western blot and immunohistochemistry workflows.

The antibody recognizes CDK6 in human, mouse, and rat samples, supporting translational studies that move between rodent disease models and clinical tissue specimens. Researchers profiling leukemia, glioblastoma, melanoma, and other CDK6-overexpressing tumor types rely on this reagent to confirm endogenous expression, validate knockdown or knockout efficiency, and map protein distribution across tissue sections by IHC.

Polyclonal reactivity provides broader epitope coverage than a single monoclonal clone, which helps when CDK6 carries post-translational modifications, appears as an alternatively spliced isoform, or is present at low abundance. The unconjugated format leaves detection chemistry open, so the antibody can be paired with HRP-, alkaline phosphatase-, biotin-, or fluorophore-labeled secondary reagents depending on the workflow.

Each vial is intended for research use only and pairs well with standard lysis buffers for western blot analysis of cyclin D-CDK6-Rb axis components.